Literature DB >> 6948383

Influence of risk factors and coagulation phenomena on the fluidity of blood in chronic arterial occlusive disease.

B Angelkort, H Kiesewetter.   

Abstract

The fluidity of blood is a significant factor for the functioning and maintenance of the microcirculation. In chronic arterial occlusive disease (COAD) the fluidity of erythrocytes is markedly reduced assessed by flow rates through a 5-micrometer pore filter system in simulation of microcirculatory conditions. Risk factors such as heavy smoking, hyperfibrinogenaemia and hypertriglyceridaemia as well as hyperfibrinogenaemia result in flow rates similar to those in patients with COAD. Isolated coagulation phenomena typical for hypercoagulability in such patients produce significantly reduced flow rates and indicate the necessity for therapeutic elimination of risk factors as well as improvement of erythrocyte fluidity, reduction of platelet hyper-reagibility and removal of hypercoagulability. Pentoxifylline effects increases in erythrocyte fluidity, decreases platelet hyper-reactivity and plasmatic hypercoagulability, and improves the fibrinolytic capacity of blood in patients with COAD.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6948383     DOI: 10.3109/00365518109097457

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest Suppl        ISSN: 0085-591X


  5 in total

1.  Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study.

Authors:  G Ciuffetti; M Mercuri; C Ott; R Lombardini; R Paltriccia; G Lupattelli; L Santambrogio; E Mannarino
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Oxpentifylline treatment of venous ulcers of the leg.

Authors:  M P Colgan; J A Dormandy; P W Jones; I G Schraibman; D G Shanik; R A Young
Journal:  BMJ       Date:  1990-04-14

3.  [Predictor function of hemorheologic parameters with reference to the incidence of manifest circulatory disorders: Concept of the Aachen study].

Authors:  H Kiesewetter; F Jung; K H Ladwig; E Waterloh; P Roebruck; R Schneider; G Kotitschke; R Bach
Journal:  Klin Wochenschr       Date:  1986-07-15

4.  24-h blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas.

Authors:  S Raptis; A Mitrakou; D Hadjidakis; E Diamantopoulos; C Anastasiou; A Fountas; R Müller
Journal:  Acta Diabetol Lat       Date:  1987 Jul-Sep

5.  The effect of denbufylline on the viscosity of rat whole blood and on the deformability (filterability) of rat blood cell suspensions.

Authors:  J J Jukna; C D Nicholson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.